Skip to main content
LPCN
NASDAQ Life Sciences

Lipocine的产后抑郁药物未达到3期主要终点，未来前景不明

feedReported by Reuters
Sentiment info
Negative
Importance info
9
Price
$9.3
Mkt Cap
$67.522M
52W Low
$2.52
52W High
$12.37
Market data snapshot near publication time

summarizeSummary

Lipocine Inc.宣布其产后抑郁药物候选物LPCN 1154的3期试验结果，显示该研究未达到其主要疗效终点。这对公司来说是一个重大挫折，尤其是考虑到其最近在2026年3月10日提交的10-K文件，该文件强调了该药物向NDA推进的进展。虽然该试验报告显示出有利的安全性特征，没有严重的不良事件，并在具有精神病史的患者子集中显示出统计学上显著的HAM-D降低，但主要终点的失败对该药物的上市路径投下了重大的不确定性。这一消息可能会对Lipocine的估值产生重大负面影响，因为市场通常会对晚期临床试验失败进行严厉的惩罚。交易者将会密切关注公司关于LPCN 1154和其更广泛的产品线的战略计划的进一步澄清。

在该公告发布时，LPCN的交易价格为$9.30，交易所为NASDAQ，所属行业为Life Sciences，市值约为$6752.2万。 52周交易区间为$2.52至$12.37。 这则新闻被评估为消极市场情绪，重要性评分为9/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed LPCN - Latest Insights

LPCN
Apr 21, 2026, 5:12 PM EDT
Filing Type: DEFA14A
Importance Score:
7
Shareholders to Vote on Significant Increase in Equity Incentive Plan Shares Amidst Financial Challenges
Sentiment: Negative
View Wiseek Article
LPCN
Apr 21, 2026, 5:01 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Lipocine Seeks Shareholder Approval for Significant Equity Incentive Plan Expansion and Elects New Chairman
Sentiment: Negative
View Wiseek Article
LPCN
Apr 21, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Lipocine Chairman Resigns Citing Differing Views on Strategic Direction
Sentiment: Negative
View Wiseek Article
LPCN
Apr 07, 2026, 6:27 PM EDT
Filing Type: 4
Importance Score:
8
Director John W. Higuchi Buys Additional $81,200 in Lipocine Stock Following Drug Trial Failure
Sentiment: Positive
View Wiseek Article
LPCN
Apr 06, 2026, 7:01 PM EDT
Filing Type: 4
Importance Score:
9
Director Makes Substantial Open Market Purchase Following Recent CEO Buy Amidst Drug Trial Setback
Sentiment: Positive
View Wiseek Article
LPCN
Apr 06, 2026, 6:33 PM EDT
Filing Type: 4
Importance Score:
8
CEO Buys $50K in Shares Following Drug Candidate Failure, Signaling Confidence
Sentiment: Positive
View Wiseek Article
LPCN
Apr 02, 2026, 9:40 AM EDT
Filing Type: 8-K
Importance Score:
8
Lipocine Details Phase 3 PPD Drug Failure, Highlights Subgroup Data for Path Forward
Sentiment: Negative
View Wiseek Article
LPCN
Apr 02, 2026, 9:35 AM EDT
Filing Type: 8-K
Importance Score:
9
Lipocine's Lead PPD Drug Fails Phase 3 Primary Endpoint, Company to Re-evaluate Options
Sentiment: Negative
View Wiseek Article
LPCN
Apr 02, 2026, 8:14 AM EDT
Source: Reuters
Importance Score:
9
Lipocine's PPD Drug Misses Phase 3 Primary Endpoint, Clouding Future Prospects
Sentiment: Negative
View Wiseek Article
LPCN
Mar 10, 2026, 6:13 AM EDT
Filing Type: 8-K
Importance Score:
8
Lipocine Reports Steep 2025 Losses & Revenue Drop, Boosts Cash via ATM, Advances PPD Drug to NDA
Sentiment: Neutral
View Wiseek Article